Ok, I will kick things off.
They have been phenomenally efficient with our capital and will deliver a multi center, multi judication phase III trial just about as cheaply as it can be done. In this regard they are setting the benchmark by which others should be judged.
They have also ensured we have little to know royalty leakage in the event we come to market. To many drug developers are giving away 10% or 12.5% there. This has a huge impact on the value of the assets in the event of approval. The Peptron deal is fantastic in this regard, uses their IP on a fixed price contract with no royalty. Management should be commended for pulling that off.
Add to My Watchlist
What is My Watchlist?
